Cardinal Health Raises Outlook After Strong Second Quarter Results

Cardinal Health reported strong financial results for its second quarter of fiscal year 2026. The company's revenue grew 19% compared to the same period last year, reaching $65.6 billion.

Operating earnings under generally accepted accounting principles (GAAP) increased by 29% to $707 million. Diluted earnings per share (EPS) under GAAP rose 19% to $1.97 per share.

On a non-GAAP basis, which excludes certain one-time items, operating earnings went up 38% to $877 million and diluted EPS grew 36% to $2.63. This exceeded Wall Street expectations.

Cardinal Health raised its profit forecast for the full year, now expecting non-GAAP EPS to be between $10.15 and $10.35. The company attributed its strong performance to robust demand for specialty drugs and overall growth across its segments.

Additionally, the company completed an annual share repurchase of $750 million and reached its targeted leverage range for debt.

It means the company expects to earn more profit than it previously predicted for the rest of the year.

Specialty drugs are advanced medicines used to treat complex or rare conditions. They are important because they drive a significant part of healthcare spending and can boost a company's revenue.

A share repurchase is when a company buys back its own shares from the market, which can increase the value of remaining shares for investors.

PRNewsWire

Revenue increased 19% to $65.6 billion GAAP 1 operating earnings increased 29% to $707 million; GAAP diluted EPS increased 19% to $1.97 Non-GAAP operating earnings increased 38% to $877 million; non-GAAP diluted EPS increased 36% to $2.63 Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance...

WSJ

Cardinal Health raised its outlook for the year after logging higher profit and revenue in its fiscal second quarter.

Reuters

Cardinal Health on Thursday raised its expectations for annual profit after surpassing Wall Street estimates for quarterly results, as it bets on robust demand for specialty medicines and strong performance across its segments.

Barrons

The pharmaceutical distributor and health services company raises its guidance for the second time.

24/7 Wall Street

Cardinal Health (NYSE: CAH) delivered a decisive second-quarter beat on February 5, 2026, with non-GAAP EPS of $2.63, surpassing the $2.38 consensus estimate by 10.5%.

Show All Sources